HLS Therapeutics Inc.

HLS

CA40390B1094

Pharmaceuticals

Delayed Toronto S.E. Other stock markets 12:41:26 18/05/2024 am IST			5-day change	1st Jan Change
3.94 ^CAD	-4.83%		+0.25%	-0.25%

09/05	Transcript : HLS Therapeutics Inc., Q1 2024 Earnings Call, May 09, 2024
09/05	HLS Therapeutics Meets Q1 Earnings Forecast, But Misses on Revs; Lowers 2024 Vascepa Guidance	MT

HLS Therapeutics Inc Announces Appointment of Independent Directors

March 13, 2018 at 03:31 am IST

HLS Therapeutics Inc. announced the completion of the amalgamation of former HLS Therapeutics Inc. and Automodular Corporation to form an amalgamated Ontario corporation to be known as HLS Therapeutics Inc. The reconstituted Board of Directors of HLS appoints Rodney Hill, Don DeGolyer and Daniel Tassé as three new independent directors.

Latest news about HLS Therapeutics Inc.

Transcript : HLS Therapeutics Inc., Q1 2024 Earnings Call, May 09, 2024	09/05
HLS Therapeutics Meets Q1 Earnings Forecast, But Misses on Revs; Lowers 2024 Vascepa Guidance	09/05	MT
HLS Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05	CI
HLS Therapeutics Brief: Q1 2024 revenue was US$12.5 million, Adjusted EBITDA was $2.7 million and cash from operations was $0.8 million	09/05	MT
HLS Therapeutics Inc Updates Consolidated Revenue Guidance for the Full Year 2024	09/05	CI
HLS Therapeutics Inc. Announces Reduce-IT Analysis Results Relating the Effects of VASCEPA	08/04	CI
Transcript : HLS Therapeutics Inc., Q4 2023 Earnings Call, Mar 14, 2024	14/03
HLS Therapeutics Reports Q4 2023 Net Loss of US$5.4 Million; Provides 2024 Outlook, Credit Agreement Update	14/03	MT
HLS Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	14/03	CI
HLS Therapeutics Brief: Q4 2023 and fiscal 2023 product sales in Canada increased 11% and 10%, respectively, in CAD, compared to same periods in 2022	14/03	MT
HLS Therapeutics Brief: Q4 2023 revenue was US$15.9 million, Adjusted EBITDA was $5.3 million and cash from operations was $3.7 million	14/03	MT
HLS Therapeutics Inc. Provides Consolidated Earnings Guidance for the Fiscal Year 2024	14/03	CI
HLS Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	14/03	CI
HLS Therapeutics Says Vascepa Now Reimbursed by British Columbia's Provincial Drug Plan	06/02	MT
HLS Therapeutics Brief: Announcing that Vascepa is now reimbursed by British Columbia's Provincial Drug Plan	06/02	MT
HLS Therapeutics Inc. Announces CFO Changes	18/12	CI
HLS Therapeutics Announcing CFO Departure; John Hanna appointed Interim CFO to replace departing CFO Tim Hendrickson	18/12	MT
HLS Therapeutics Brief: Announcing CFO Departure; John Hanna appointed Interim CFO to replace departing CFO Tim Hendrickson	18/12	MT
HLS Therapeutics Brief: Adds Analysis Also Found Icosapent Ethyl Was Associated with a 41% Reduction in Total Events Compared with Placebo	15/11	MT
HLS Therapeutics Brief: Says New REDUCE-IT Analyses Show Vascepa (Icosapent Ethyl) Associated with 29% Relative Risk Reduction Vs Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline	15/11	MT
HLS Therapeutics Inc. Announces Results from New REDUCE-IT Analyses	15/11	CI
HLS Therapeutics Inc.'s Equity Buyback announced on November 10, 2022, has expired.	13/11	CI
HLS Therapeutics Downgraded to Hold at Stifel GMP on Revenue Concerns; Price Target Cut to C$5.00	10/11	MT
HLS Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11	CI
Tranche Update on HLS Therapeutics Inc.'s Equity Buyback Plan announced on November 10, 2022.	09/11	CI

Chart HLS Therapeutics Inc.

Duration

Period

More charts

Company Profile

HLS Therapeutics Inc. is a pharmaceutical company. It is focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. It is engaged in addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. It is also focused on products targeting the central nervous system and cardiovascular therapeutic areas. Its products include Clozaril, CSAN Pronto, MyCare Insite, MyCare Psychiatry, PERSERIS, Trinomia and Vascepa. Its lead product is Clozaril, which is an atypical antipsychotic indicated for the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is a capillary point-of-care medical device designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. Trinomia product related to the treatment of cardiovascular disease.

Sector

Pharmaceuticals

Calendar

07/06/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for HLS Therapeutics Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.896 USD

Average target price

3.885 USD

Spread / Average Target

+34.15%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Pharmaceuticals Wholesale

	1st Jan change	Capi.
HLS THERAPEUTICS INC.	-0.25%	92.34M
MCKESSON CORPORATION	+21.79%	73.38B
CARDINAL HEALTH, INC.	-1.99%	24.13B
SINOPHARM GROUP CO. LTD.	+7.58%	8.78B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD	+10.52%	8.59B
HUADONG MEDICINE CO., LTD	-19.56%	8.06B
H. LUNDBECK A/S	+14.16%	5.26B
EBOS GROUP LIMITED	-0.93%	4.21B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD	+12.13%	4.17B
GALENICA AG	-2.54%	3.89B

Pharmaceuticals Wholesale